WAVE Life Sciences To Present At The Jefferies Gene Technology Investor Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies Gene Technology Investor Summit on Thursday, October 12, 2017 at 8:20 A.M. ET in New York, New York.

A live webcast will also be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. After the live webcast, the event will remain archived on the corporate website for a limited time.

About Wave Life Sciences

Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases. Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

Forward Looking Information

This press release contains forward-looking statements, including statements relating to the significance of the paper; the importance of the paper’s findings in the field of nucleic acid therapeutics; the distinguishing features of Wave’s drug development platform and the potential benefits thereof. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including risks and uncertainties associated with Wave’s stereopure chemistry platform, the drug development and regulatory approval process; and the commercialization, development and acceptance of therapies with new technologies, as well as other risks and uncertainties that are described in the Risk Factors section of Wave’s most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the parties assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.